Topical Treatment of Kaposi’s Sarcoma, Basal Cell Carcinoma and Solar Keratosis with Ointment of BCG and Cord Factor

Abstract

4 patients with Kaposi’s sarcoma and 1 patient with basal cell carcinoma and solar keratosis were successfully treated with topical application of an ointment containing killed BCG and cord factor.

Topical treatments for Kaposi sarcoma: A systematic review

“… 39 Topical BCG and cord factor was used for four patients in a case study and all achieved complete response. 40 In one multicenter study, 4,4′‐dihydroxybenzophenone‐2,4‐dinitrophenylhydrazone (A007) was used a topical KS treatment in four patients; two achieved partial response and two had no response. 9 Topical calcipotriene was used in eight patients in a single case series; of eight patients, one achieved complete response, three achieved partial response and four had no response.…”

Effect of a Single Injection of Cyclophosphamide on Immunization Therapy of Metastases Remaining after Excision of Dermal Primary Tumors in Guinea Pigs

“…The use of BCG KCE might reduce toxic side effects and improve effectiveness. BCG KCE were successfully used in patients with skin tumors such as mycosis fungoides, Kaposi's sarcoma, basal cell carcinoma, and solar keratosis by administration of the adjuvant into the malignant lesions in order to potentiate spe cific antitumor responses [8,9; Mitsuhashi, personal commun.]. These antitumor responses may be, how ever, subverted by specific and nonspecific im munosuppression resulting in failure of immunoadjuvants in therapy of human cancer.…”

“…It is important to manipulate the immune system with the aid of immunoadjuvants so as to effect the destruction of métastasés which remain after sur gery. Immunoadjuvants such as emulsions containing killed BCG bacilli (BCG KCE) or BCG cell walls (BCG CWE) have been reported to be immunotherapeutically effective in the treatment of metastatic can cer in guinea pigs [1][2][3][4][5][6][7] and in human skin tumors [8,9]. However, insignificant therapeutic effects were obtained in experiments in which nonliving BCG preparations were used to affect the métastasés after excision of the dermal tumor transplant.…”

Immunotherapy of guinea pig line 10 hepatoma with nonliving BCG cells in aqueous medium

“…In the experi-ence of one of the authors (A.B. ), the therapy of skin tumors in humans may be achieved with substantially smaller amounts of nonviable BCG than have been used in guinea pigs (9,10). A recent report by McLaughlin et al (19) describes a similar synergistic tumor-regressive activity between deproteinized (not delipidated) BCG cell walls and Re ET in oil-in-water emulsion.…”